(VOVWORLD) - Vietnam on Thursday began human trials of Nanocovax, a COVID-19 vaccine developed by Ho Chi Minh city’s Nanogen Pharmaceutical Biotechnology company.
 Registration of Nanocovax trial at Military Medical Academy on December 10, 2020 (Photo: vnexpress.net) |
200 people have volunteered to be part of the vaccine trials.
Nanocovax will first be tested on 60 selected volunteers between 18 and 50 years of age in a phase that will be completed in February. Each volunteer will receive two shots of the vaccine 28 days apart.
Do Minh Si, Nanogen’s R&D Manager, said: “We really hope we will be successful with this trial. With the support of the Ministry of Health and the Ministry of Science and Technology, we hope we will soon have a vaccine to protect Vietnam from COVID-19.”
Phase 1 will test the vaccine mainly for its safety. Phase 2 will run from next February to August, and Phase 3 is scheduled from next August to February of 2022.